DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment
Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll of morbidity, mortality, and economic burden. Within this landscape, NAFLD/nonalcoholic steatohepatitis (NASH) recently renamed MASH (metabolic dysfunction-associated steatohepatitis) assumes prominence as a pivotal contributor. NAFLD, a comprehensive term encapsulating a spectrum of liver afflictions, encompasses everything from benign steatosis to progressive hepatocellular injury accompanied by fibrosis, cirrhosis, and, in…
Breakthroughs in Parkinson’s Management: Key Findings from Neuroderm’s ND0612 Studies
NeuroDerm's ND0612 introduces a pioneering approach to Parkinson's disease management with its self-administered continuous subcutaneous infusion of levodopa/carbidopa. Unlike traditional oral formulations, ND0612 bypasses the gastrointestinal tract, offering increased bioavailability and potentially more reliable relief from motor fluctuations By providing a continuous, adjustable dose of levodopa/carbidopa via subcutaneous infusion, ND0612 aims to extend the therapeutic window for Parkinson's patients. This innovative approach seeks to minimize motor fluctuations and optimize patients' "ON" time, thereby offering greater daily-life predictability and independence compared to conventional oral treatments Neuroderm made a significant impact at…
Charting Progress: Ozanimod’s Influence on Brain Dynamics in RMS
ZEPOSIA (ozanimod), a breakthrough approved in March 2020 for Relapsing Forms of Multiple Sclerosis (RMS), utilizes oral sphingosine 1-phosphate (S1P) receptor modulation to impede lymphocyte migration, offering a novel approach in multiple sclerosis treatment. ENLIGHTEN (NCT04140305) explores ozanimod's impact on early RMS. Utilizing advanced imaging techniques, it analyzes whole brain volume (WBV) changes over 1 year, shedding light on potential therapeutic benefits. At the American Academy of Neurology conference 2024, Bristol Myers Squibb reported the interim findings of the ENLIGHTEN Study. This multicenter, longitudinal, single-arm study explores cognitive processing speed…
-Agonist.png "Toll-like Receptors Agonist")
